37 results
8-K
EX-99.1
ATHA
Athira Pharma Inc
15 May 24
Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
4:10pm
of the change in Event-Related-Potential (ERP) P300 latency and cognitive assessment (ADAS-Cog13), was not met by protocoled analysis compared with placebo
PRE 14A
ATHA
Athira Pharma Inc
28 Mar 24
Preliminary proxy
8:47am
based on the compensation consultant recommendations, our chief executive officer’s own assessment of Company and individual performance … strategy (weighted 25%), commercial formulation, clinical supply manufacture, and dose assessment (weighted 15%), IND-enabling studies and other scientific
8-K
EX-99.1
jtdi1hx3upb6i
22 Feb 24
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
4:10pm
8-K
EX-99.1
l5uwmpura3cebaxn 5kg
8 Jan 24
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
7:11am
8-K
EX-99.1
x0p46pkw97l7 eh
17 Oct 22
Results support potential clinically meaningful activity of fosgonimeton without background therapy and mitigate program risk
8:30am
8-K
EX-99.2
yctynz m86w0f9e3k8
17 Oct 22
Results support potential clinically meaningful activity of fosgonimeton without background therapy and mitigate program risk
8:30am
8-K
EX-99.2
nxabfaslu3ikt
22 Jun 22
Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
7:05am
8-K
EX-99.1
uc6y65zr5f7 av4etlj
22 Jun 22
Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
7:05am
DEFA14A
oeokt7d
26 Apr 22
Additional proxy soliciting materials
8:11am
DEFA14A
xg4x43obkibajn
11 Apr 22
Additional proxy soliciting materials
4:36pm